Navigation Links
Surveyed U.S. Neurologists Are More Likely Than Payers to Consider Biogen Idec's Tecfidera to be a Breakthrough in the Treatment of Multiple Sclerosis
Date:9/3/2013

predecessor compounds.

The report also finds that novel late-stage emerging disease-modifying therapies (DMTs) for the treatment of MS—Genzyme/Bayer HealthCare's Lemtrada, Biogen Idec/AbbVie's daclizumab and Roche/Genentech's ocrelizumab—will generally be reserved for treatment-refractory patients, likely reflecting safety concerns about each. Furthermore, while surveyed MCO PDs/MDs anticipate formulary coverage of these DMTs on their commercial plans broadly similar to their coverage of existing DMTs, the new entrants are more likely to be subject to indications restrictions than current DMTs and emerging reformulations.

"As more DMTs enter the MS market in the U.S., uptake and coverage of each agent will depend on clear demonstration of its value to stakeholders, driven in particular by the balance of cost, advancements in efficacy and acceptable safety," said Decision Resources Senior Director Jonathan Searles. "Moreover, MCO PDs/MDs indicate that post-marketing studies supporting the health economic benefits of a DMT will be an influential factor in determining future formulary coverage—as a result, generating compelling evidence of pharmacoeconomic benefit represents an important potential opportunity for nonclinical differentiation."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resourc
'/>"/>

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Up to Sixty Percent of Surveyed U.S. Managed Care Organization Directors Expect to Cover Key Emerging Therapies for Parkinsons Disease on Their Largest Commercial Plan
2. The Majority of Surveyed Oncologists Prescribe Avastin Off-label to Their Ovarian Cancer Patients; However Approximately Half Encounter Access and Reimbursement Hurdles
3. After Reviewing Brief Product Profiles, Surveyed Physicians Believe that Likely Candidates for Late-Phase Chronic Kidney Disease Products from AbbVie, Mitsubishi Tanabe, Eli Lilly, Concert, Fibrogen and Pfizer are Typically Stage 3b and 4 Patients
4. Surveyed U.S. and European Neurologists Identify Better Seizure-Free Efficacy as One of the Greatest Unmet Needs in Treating Partial-Onset Seizures in Refractory Epilepsy Patients
5. One in Four Surveyed EU5 Physicians Has Been Required to Change a Prescription for Some or Most of Their HIV Patients in the Past Twelve Months, Primarily to Reduce Costs
6. Rising Drug Resistance is Driving Early-Line Use of Powerful Antibiotics Such as Carbapenems for Gram-Negative Infections, According to Surveyed EU5 Physicians
7. For Second- and Subsequent-Line Metastatic Castrate-Resistant Prostate Cancer, Surveyed Oncologists Indicate that Improved Symptom Control and Quality of Life is one of the Greatest Unmet Needs
8. For Chronic Obstructive Pulmonary Disease, Surveyed Pulmonologists Indicate That Improved Effect on Quality of Life is One of the Greatest Unmet Needs
9. The Majority of Surveyed Gastroenterologists in the EU5 Identify Remicade as Their Most Preferred Biologic for the Treatment of Ulcerative Colitis
10. For Treating Clostridium difficile Infections, Surveyed Infectious Disease Specialists Agree That Effect on Recurrence Rate is One of the Drug Attributes that Most Influences Their Prescribing Decisions
11. Surveyed U.S. Pulmonologists Expect to Treat Nearly 50 Percent of Their Severe, Refractory Asthma Patients With a Biologic or Biosimilar Version of Xolair By the End of 2018
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)...  Syneron Medical Ltd. (NASDAQ: ELOS ), a leading ... three month period ended June 30, 2015. ... Highlights: , Revenue of $73.5 million, up ... American product sales grew 45% year-over-year. , International sales ... product growth in the EMEA region and 25% product growth ...
(Date:8/3/2015)... 3, 2015  Luminex Corporation (NASDAQ: LMNX ) ... June 30, 2015.  Financial and operating highlights for the ... quarter 2015 revenue by 6 percent to $58.9 million, ... second quarter 2015 assay revenue by 22 percent to ... 2014. , Increased Q2 2015 royalty revenue by ...
(Date:8/3/2015)... Diplomat Pharmacy, Inc. (NYSE: DPLO ), the ... quarter ended June 30, 2015. All comparisons, unless otherwise noted, ... Second Quarter 2015 Highlights include: , Revenue ... , Total prescriptions dispensed of 234,000, an increase of ... , Adjusted EBITDA of $22.7 million, an increase of 287% ...
Breaking Medicine Technology:Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 2Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 3Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 4Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 5Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 6Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 7Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 8Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 9Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 10Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 11Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 12Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 13Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 14Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 15Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 16Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 17Luminex Corporation Reports Record 2nd Quarter 2015 Results 2Luminex Corporation Reports Record 2nd Quarter 2015 Results 3Luminex Corporation Reports Record 2nd Quarter 2015 Results 4Luminex Corporation Reports Record 2nd Quarter 2015 Results 5Luminex Corporation Reports Record 2nd Quarter 2015 Results 6Luminex Corporation Reports Record 2nd Quarter 2015 Results 7Luminex Corporation Reports Record 2nd Quarter 2015 Results 8Luminex Corporation Reports Record 2nd Quarter 2015 Results 9Luminex Corporation Reports Record 2nd Quarter 2015 Results 10Luminex Corporation Reports Record 2nd Quarter 2015 Results 11Luminex Corporation Reports Record 2nd Quarter 2015 Results 12Luminex Corporation Reports Record 2nd Quarter 2015 Results 13Luminex Corporation Reports Record 2nd Quarter 2015 Results 14Luminex Corporation Reports Record 2nd Quarter 2015 Results 15Luminex Corporation Reports Record 2nd Quarter 2015 Results 16Diplomat Announces 2nd Quarter 2015 Financial Results 2Diplomat Announces 2nd Quarter 2015 Financial Results 3Diplomat Announces 2nd Quarter 2015 Financial Results 4Diplomat Announces 2nd Quarter 2015 Financial Results 5
(Date:8/4/2015)... ... August 04, 2015 , ... ... at unique artistic expressions from a diverse group of exceptionally talented female artists. ... Music & Art Festival on September 25-27, 2015 in Downtown Las Vegas. Curated ...
(Date:8/4/2015)... ... August 04, 2015 , ... MedicaSoft ... Office of the National Coordinator for Health Information Technology (ONC-HIT) 2014 Edition ... highest quality personal health record and patient portal solution to healthcare providers ...
(Date:8/4/2015)... , ... August 04, 2015 , ... ... older brings an automatic end to driving, says the August 2015 Harvard Health ... is okay to drive. It requires an individual assessment of skills," says Lissa ...
(Date:8/4/2015)... ... August 04, 2015 , ... METTLER TOLEDO has announced an ... researchers from Lubrizol, Pfizer, and Merck. This free online seminar will be ... timelines often require informed decisions with limited process understanding. Established methods have ...
(Date:8/4/2015)... ... August 04, 2015 , ... Half of consumers are ... board-certified is increasingly influential in their choice of practitioner, according to new survey ... Survey on Cosmetic Dermatologic Procedures reflects overall consumer views on cosmetic medical treatments ...
Breaking Medicine News(10 mins):Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 2Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 3Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 4Health News:MedicaSoft's HealthCenter Earns ONC-HIT Certification from Drummond Group 2Health News:MedicaSoft's HealthCenter Earns ONC-HIT Certification from Drummond Group 3Health News:Assessment Can Help Older Drivers Keep Driving Safely, from the August 2015 Harvard Health Letter 2Health News:METTLER TOLEDO Announces New Process Chemistry and Scale-up Online Seminar 2Health News:ASDS Survey: Half of Consumers Considering Cosmetic Procedure 2Health News:ASDS Survey: Half of Consumers Considering Cosmetic Procedure 3Health News:ASDS Survey: Half of Consumers Considering Cosmetic Procedure 4
... -- The American College of Physicians (ACP) has received a ... of a patient-centered medical home (PCMH). The grant, part ... underwrite a 10-month study which began in November. ACP ... a conceptual model of care whose goal is to put ...
... 15 years, use of opioid medications to treat patients ... patients were more likely to receive opioids than patients ... the January 2 issue of JAMA. , In ... the problem of inadequately treated pain. Also, racial and ...
... January 1 issue of the journal SLEEP finds that ... cardiovascular responses during recovery from maximal exercise. These ... heart rate during recovery, and may be an early ... study, authored by Trent A. Hargens, PhD, of Virginia ...
... treat chronic and recurrent tonsillitis substantially improve a patients ... to two new studies published as a supplement to ... , In one study involving 72 adults, patients showed ... Adenoid Health Status Instrument (TAHSI), a scale used to ...
... ... Boards Merge, CANTON, Ohio, Dec. 31 Two county boards have,merged ... Alcohol and Drug Addiction Services Board of Stark County are,now a single ... "The combined Board will create a stronger advocate for people with,mental ...
... YORK, Dec. 31 The New Year ... finally lose those excess pounds in a ... to this report from GlaxoSmithKline at:, http://media.medialink.com/WebNR.aspx?story=34274 ... audio, text, graphics and,photos for free and ...
Cached Medicine News:Health News:American College of Physicians receives grant to study cost of patient-centered medical home 2Health News:Use of opioids for pain in ERs on the rise, but racial differences in use still exist 2Health News:Use of opioids for pain in ERs on the rise, but racial differences in use still exist 3Health News:Undiagnosed OSA patients have altered cardiovascular responses during exercise recovery 2Health News:Undiagnosed OSA patients have altered cardiovascular responses during exercise recovery 3Health News:Combined Boards Provide Better Care to More Clients More Efficiently 2
... just about everything imaginable that might have to ... is designed for long term storage under archival ... over metal systems is overlooked, while the natural ... of desiccator and insulator, providing an environment that ...
A prepared Microscope Slide Cataloging and Storage System....
... Our moisture resistant, plastic covered ... high, each supporting up to 500 ... weight. Each box accommodates 2000 slides ... your varied storage requirements. Come unassembled ...
Shandon Plastic Slide Boxes...
Medicine Products: